Investigating COVID-19 infection in patients with acute myeloid leukaemia (AML) undergoing chemotherapy
- Conditions
- Acute myeloid leukaemia, COVID-19 (SARS-CoV-2 infection)Cancer
- Registration Number
- ISRCTN16865769
- Lead Sponsor
- niversity of Birmingham
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 321
1. Acute myeloid leukaemia (AML) including known AML presenting with relapse or Myelodysplastic Syndrome With Excess Blasts (MDS-EB2)
2. Currently receiving (at any treatment stage), or planned for, intensive (i.e. curative intent) or non-intensive chemotherapy. Intensive treatment includes regimens including Daunorubicin/Cytarabine, Fludarabine/Cytarabine/Idarubicin, intermediate/high dose Cytarabine, CPX-351, Gemtuzumab Ozogamacin, Midostaurin. Non-intensive treatments include Azacitidine, low dose Cytarabine, and Venetoclax based regimens.
3. Written informed consent to participate
1. Aged <16 years
2. Undergoing allogeneic stem cell transplant at trial entry
3. Supportive care only (including hydroxycarbamide alone)
4. Acute promyelocytic leukaemia (APML)
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of COVID-19 infection developing during AML treatment measured using SAR-CoV-2 PCR test and from hospital records from baseline until 4 weeks subsequent to the last cycle of treatment
- Secondary Outcome Measures
Name Time Method